ReviewBiochemical pharmacology2014
Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles.
Review in Biochemical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 107 citations in OpenAlex.
- Cerebral Intramural Cells: A Missing Cellular Link Between Vascular Aging and Alzheimer's Disease.International journal of molecular sciences · 2026Review
- Multifunctional Tacrine-Quinoline Hybrids as Cholinesterase Inhibitors, Aβ Aggregation Blockers, and Metal Chelators for Alzheimer's Therapy.Molecules (Basel, Switzerland) · 2025Article
- Astrocytic Hevin/SPARCL-1 Regulates Cognitive Decline in Pathological and Normal Brain Aging.Aging cell · 2025Article
- Population-Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study.Clinical pharmacology and therapeutics · 2025Article
- Oxidative stress: from molecular studies to clinical intervention strategies.Frontiers in molecular biosciences · 2025Review
- Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History.Journal of clinical medicine · 2024Review
- Advancements and Challenges in Antiamyloid Therapy for Alzheimer's Disease: A Comprehensive Review.International journal of Alzheimer's disease · 2024Review
- Pre- and post-treatment of α-Tocopherol on cognitive, synaptic plasticity, and mitochondrial disorders of the hippocampus in icv-streptozotocin-induced sporadic Alzheimer's-like disease in male Wistar rat.Frontiers in neuroscience · 2023Article
- Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer's disease.Heliyon · 2022Review
- Curcumin Scaffold as a Multifunctional Tool for Alzheimer's Disease Research.Molecules (Basel, Switzerland) · 2022Review
- Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents.JAMA network open · 2022Article
- No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer's disease and related dementia: results from the Drug Repurposing for Effective Alzheimer's Medicines study.Brain communications · 2022Article
- Accelerated Epigenetic Age in Normal Cognitive Aging of Korean Community-Dwelling Older Adults.Biological research for nursing · 2021Article
- System biology and bioinformatics pipeline to identify comorbidities risk association: Neurodegenerative disorder case study.PloS one · 2021Article
- Microtubule Dysfunction: A Common Feature of Neurodegenerative Diseases.International journal of molecular sciences · 2020Review
- Overdosing on iron: Elevated iron and degenerative brain disorders.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Article
- Tau Protein and Its Role in Blood-Brain Barrier Dysfunction.Frontiers in molecular neuroscience · 2020Review
- Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study.Alzheimer's & dementia (New York, N. Y.) · 2020Article
- ApoE4: an emerging therapeutic target for Alzheimer's disease.BMC medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The bulk of AD research during the last 25 years has been Aβ-centric based on a strong faith in the Amyloid Cascade Hypothesis which is not supported by the data on humans. To date, Aβ-based therapeutic clinical trials on sporadic cases of AD have been negative. Although most likely the major reason for the failure is that Aβ is not an effective therapeutic target for sporadic AD, initiation of the treatment at mild to moderate stages of the disease is blamed as too late to be effective. Clinical trials on presymptomatic familial AD cases have been initiated with the logic that Aβ is a trigger of the disease and hence initiation of the Aβ immunotherapies several years before any clinical symptoms would be effective. There is an urgent need to explore targets other than Aβ. There is now increasing interest in inhibiting tau pathology, which does have a far more compelling rationale than Aβ. AD is multifactorial and over 99% of the cases are the sporadic form of the disease. Understanding of the various etiopathogenic mechanisms of sporadic AD and generation of the disease-relevant animal models are required to develop rational therapeutic targets and therapies. Treatment of AD will require both inhibition of neurodegeneration and regeneration of the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.